Abstract
Assessment of fecal calprotectin, a surrogate marker of mucosal inflammation, is a promising means to monitor therapeutic response in pediatric inflammatory bowel disease, especially if the result is readily available. We tested the performance of a novel calprotectin rapid test, Quantum Blue, versus the conventional enzyme-linked immunosorbent assay in 134 stool samples from 56 pediatric patients with Crohn disease. The intraclass correlation coefficient analysis reflected good agreement (intraclass correlation coefficient 0.97 [95% confidence interval 0.95-0.98]) but agreement was better in lower values, where dilutions were not required. Using a cutoff of 100μg/g for normal values, the percentage agreement between the 2 tests was 87%. The optimal cutoff values to guide clinical decisions in the therapy of inflammatory bowel disease have yet to be determined.
| Original language | English |
|---|---|
| Pages (from-to) | 436-439 |
| Number of pages | 4 |
| Journal | Journal of Pediatric Gastroenterology and Nutrition |
| Volume | 55 |
| Issue number | 4 |
| DOIs | |
| State | Published - Oct 2012 |
Keywords
- Fecal biomarkers
- Inflammatory bowel disease
- Pediatric
Fingerprint
Dive into the research topics of 'Rapid test for fecal calprotectin levels in children with Crohn disease'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver